HC Wainwright Lowers Earnings Estimates for Kodiak Sciences

Kodiak Sciences Inc. (NASDAQ:KOD) – Equities research analysts at HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for Kodiak Sciences in a note issued to investors on Monday, August 17th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings of ($0.89) per share for the quarter, down from their previous forecast of ($0.80). HC Wainwright currently has a “Buy” rating and a $58.00 price target on the stock. The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.74) per share. HC Wainwright also issued estimates for Kodiak Sciences’ Q4 2026 earnings at ($0.89) EPS, FY2026 earnings at ($3.75) EPS, FY2027 earnings at ($3.27) EPS, FY2028 earnings at ($2.01) EPS, FY2029 earnings at $0.18 EPS and FY2030 earnings at $3.04 EPS.

Kodiak Sciences (NASDAQ:KOD) last announced its earnings results on Wednesday, August 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by ($0.09).

Other research analysts have also recently issued research reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kodiak Sciences in a research note on Friday, July 10th. Wall Street Zen lowered Kodiak Sciences from a “hold” rating to a “sell” rating in a research note on Saturday. JPMorgan Chase & Co. raised their target price on Kodiak Sciences from $56.00 to $66.00 and gave the stock an “overweight” rating in a report on Monday, August 3rd. Finally, Chardan Capital upgraded Kodiak Sciences from a “neutral” rating to a “buy” rating and lifted their target price for the company from $14.00 to $61.00 in a research report on Monday, May 11th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $48.14.

Kodiak Sciences Trading Down 0.8%

Shares of NASDAQ KOD opened at $40.65 on Wednesday. Kodiak Sciences has a 12-month low of $8.29 and a 12-month high of $47.84. The firm has a market capitalization of $2.54 billion, a price-to-earnings ratio of -9.70 and a beta of 2.21. The firm has a 50 day moving average of $39.52 and a 200 day moving average of $35.23.

Institutional Trading of Kodiak Sciences

Several hedge funds have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company increased its holdings in shares of Kodiak Sciences by 31.8% in the 1st quarter. The Manufacturers Life Insurance Company now owns 120,629 shares of the company’s stock worth $4,598,000 after buying an additional 29,121 shares during the last quarter. California State Teachers Retirement System grew its stake in Kodiak Sciences by 1,358.9% during the 1st quarter. California State Teachers Retirement System now owns 29,396 shares of the company’s stock worth $1,121,000 after buying an additional 27,381 shares during the last quarter. Profund Advisors LLC acquired a new stake in Kodiak Sciences in the 4th quarter worth approximately $618,000. PSP Research LLC purchased a new position in shares of Kodiak Sciences in the fourth quarter worth $543,000. Finally, Artia Global Partners LP acquired a new stake in shares of Kodiak Sciences during the fourth quarter worth $476,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

About Kodiak Sciences

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.